In a recent development, Aurobindo Pharma announced that its subsidiary, Auro Vaccines, has terminated a license agreement with Singapore-based Hilleman Laboratories. The agreement was meant to develop and commercialize a pentavalent vaccine candidate aimed at children’s immunization.
About the Author
